The Research report on Molecular Cytogenetics Market provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the market along with the estimates and forecasts of the revenue and market share analysis.
MarketsandMarkets published a report which says that the molecular cytogenetics market is projected to reach USD 2.52 Billion, at a CAGR of 10.1%
Don’t miss out on business opportunities in Molecular Cytogenetics Market.
Molecular Cytogenetics Market
The high incidence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure have resulted in the increasing use of molecular cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies.
Molecular Cytogenetics Market Dynamics;
Key Drivers:
- Increasing Incidence of Genetic Disorders and Cancer
- Growing Focus on Targeted Cancer Treatment
- Increasing Aging Population and Subsequent Rise in Prevalence of Chronic Diseases
- Increasing Penetration of Molecular Cytogenetics in Clinical Pathological Testing
Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=148469224
Major Key players in the molecular cytogenetics Market;
F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Gene Technology (U.K.), and Applied Spectral Imaging (U.S.).
Detailed Profile of Major Key Players (Molecular Cytogenetics Market):
F. Hoffmann-La Roche Ltd. (Switzerland) was the largest player in the global molecular cytogenetics market, with a share of 15.2% in 2015. The company has a strong presence in the U.S. and in regions such as Europe, the Middle East, and Africa (EMEA), Asia-Pacific, Latin America, and Japan. It focuses on acquisition as its key growth strategy. For instance, in January 2014, Roche acquired Genia Technologies, Inc. (U.S.). This acquisition strengthened Roche’s next-generation sequencing pipeline. Moreover, in February 2015, Roche acquired Signature Diagnostics AG (Germany).
Danaher Corporation (U.S.) was the second-largest player, with a market share of 13.7% in 2015. Leica Microsystems is a subsidiary of Danaher that develops molecular cytogenetics instruments and kits. The company has plants in Germany, Austria, Switzerland, the U.K., China, and Singapore. It has a presence in over 100 countries—with sales and service organizations in 20 countries and an international network of distribution partners.
Download PDF: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224
